370 related articles for article (PubMed ID: 30675694)
1. Physiologically Based Pharmacokinetic Modelling of Hyperforin to Predict Drug Interactions with St John's Wort.
Adiwidjaja J; Boddy AV; McLachlan AJ
Clin Pharmacokinet; 2019 Jul; 58(7):911-926. PubMed ID: 30675694
[TBL] [Abstract][Full Text] [Related]
2. The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose.
Mueller SC; Majcher-Peszynska J; Uehleke B; Klammt S; Mundkowski RG; Miekisch W; Sievers H; Bauer S; Frank B; Kundt G; Drewelow B
Eur J Clin Pharmacol; 2006 Jan; 62(1):29-36. PubMed ID: 16341856
[TBL] [Abstract][Full Text] [Related]
3. No clinically relevant CYP3A induction after St. John's wort with low hyperforin content in healthy volunteers.
Mueller SC; Majcher-Peszynska J; Mundkowski RG; Uehleke B; Klammt S; Sievers H; Lehnfeld R; Frank B; Thurow K; Kundt G; Drewelow B
Eur J Clin Pharmacol; 2009 Jan; 65(1):81-7. PubMed ID: 18762932
[TBL] [Abstract][Full Text] [Related]
4. Hyperforin in St. John's wort drug interactions.
Madabushi R; Frank B; Drewelow B; Derendorf H; Butterweck V
Eur J Clin Pharmacol; 2006 Mar; 62(3):225-33. PubMed ID: 16477470
[TBL] [Abstract][Full Text] [Related]
5. Understanding drug interactions with St John's wort (Hypericum perforatum L.): impact of hyperforin content.
Chrubasik-Hausmann S; Vlachojannis J; McLachlan AJ
J Pharm Pharmacol; 2019 Jan; 71(1):129-138. PubMed ID: 29411879
[TBL] [Abstract][Full Text] [Related]
6. No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John's wort extract.
Arold G; Donath F; Maurer A; Diefenbach K; Bauer S; Henneicke-von Zepelin HH; Friede M; Roots I
Planta Med; 2005 Apr; 71(4):331-7. PubMed ID: 15856409
[TBL] [Abstract][Full Text] [Related]
7. St. John's wort extract with a high hyperforin content does not induce P-glycoprotein activity at the human blood-brain barrier.
El Biali M; Wölfl-Duchek M; Jackwerth M; Mairinger S; Weber M; Bamminger K; Poschner S; Rausch I; Schindler N; Lozano IH; Jäger W; Nics L; Tournier N; Hacker M; Zeitlinger M; Bauer M; Langer O
Clin Transl Sci; 2024 May; 17(5):e13804. PubMed ID: 38700454
[TBL] [Abstract][Full Text] [Related]
8. Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures.
Komoroski BJ; Zhang S; Cai H; Hutzler JM; Frye R; Tracy TS; Strom SC; Lehmann T; Ang CY; Cui YY; Venkataramanan R
Drug Metab Dispos; 2004 May; 32(5):512-8. PubMed ID: 15100173
[TBL] [Abstract][Full Text] [Related]
9. Effect of the St. John's wort constituent hyperforin on docetaxel metabolism by human hepatocyte cultures.
Komoroski BJ; Parise RA; Egorin MJ; Strom SC; Venkataramanan R
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6972-9. PubMed ID: 16203790
[TBL] [Abstract][Full Text] [Related]
10. Clinical risks of St John's Wort (Hypericum perforatum) co-administration.
Soleymani S; Bahramsoltani R; Rahimi R; Abdollahi M
Expert Opin Drug Metab Toxicol; 2017 Oct; 13(10):1047-1062. PubMed ID: 28885074
[TBL] [Abstract][Full Text] [Related]
11. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity.
Wang Z; Gorski JC; Hamman MA; Huang SM; Lesko LJ; Hall SD
Clin Pharmacol Ther; 2001 Oct; 70(4):317-26. PubMed ID: 11673747
[TBL] [Abstract][Full Text] [Related]
12. No Clinically Relevant Interactions of St. John's Wort Extract Ze 117 Low in Hyperforin With Cytochrome P450 Enzymes and P-glycoprotein.
Zahner C; Kruttschnitt E; Uricher J; Lissy M; Hirsch M; Nicolussi S; Krähenbühl S; Drewe J
Clin Pharmacol Ther; 2019 Aug; 106(2):432-440. PubMed ID: 30739325
[TBL] [Abstract][Full Text] [Related]
13. Variability in PXR-mediated induction of CYP3A4 by commercial preparations and dry extracts of St. John's wort.
Gödtel-Armbrust U; Metzger A; Kroll U; Kelber O; Wojnowski L
Naunyn Schmiedebergs Arch Pharmacol; 2007 Aug; 375(6):377-82. PubMed ID: 17593354
[TBL] [Abstract][Full Text] [Related]
14. St. John's Wort Formulations Induce Rat CYP3A23-3A1 Independent of Their Hyperforin Content.
Schäfer AM; Rysz MA; Schädeli J; Hübscher M; Khosravi H; Fehr M; Seibert I; Potterat O; Smieško M; Meyer Zu Schwabedissen HE
Mol Pharmacol; 2023 Dec; 105(1):14-22. PubMed ID: 37863663
[TBL] [Abstract][Full Text] [Related]
15. Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients.
Goey AK; Mooiman KD; Beijnen JH; Schellens JH; Meijerman I
Cancer Treat Rev; 2013 Nov; 39(7):773-83. PubMed ID: 23394826
[TBL] [Abstract][Full Text] [Related]
16. Hyperforin contributes to the hepatic CYP3A-inducing effect of Hypericum perforatum extract in the mouse.
Cantoni L; Rozio M; Mangolini A; Hauri L; Caccia S
Toxicol Sci; 2003 Sep; 75(1):25-30. PubMed ID: 12857935
[TBL] [Abstract][Full Text] [Related]
17. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme.
Markowitz JS; Donovan JL; DeVane CL; Taylor RM; Ruan Y; Wang JS; Chavin KD
JAMA; 2003 Sep; 290(11):1500-4. PubMed ID: 13129991
[TBL] [Abstract][Full Text] [Related]
18. Food constituent- and herb-drug interactions in oncology: Influence of quantitative modelling on Drug labelling.
Pilla Reddy V; Jo H; Neuhoff S
Br J Clin Pharmacol; 2021 Oct; 87(10):3988-4000. PubMed ID: 33733472
[TBL] [Abstract][Full Text] [Related]
19. Metabolism of hyperforin, the active constituent of St. John's wort, in human liver microsomes.
Hokkanen J; Tolonen A; Mattila S; Turpeinen M
Eur J Pharm Sci; 2011 Feb; 42(3):273-84. PubMed ID: 21168483
[TBL] [Abstract][Full Text] [Related]
20. The effect of St John's wort on the pharmacokinetics of docetaxel.
Goey AK; Meijerman I; Rosing H; Marchetti S; Mergui-Roelvink M; Keessen M; Burgers JA; Beijnen JH; Schellens JH
Clin Pharmacokinet; 2014 Jan; 53(1):103-10. PubMed ID: 24068654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
